This is a 12th case report on olanzapine induced hypothermia and based on the results of literature search, by far is the youngest case ever is reported. The hypothermia occurred during the refeeding phase, despite a weight gain since increasing the dosage from 5 mg to 7.5 mg olanzapine. Our recent literature search found 11 published cases of olanzapine treatment associated with hypothermia. Olanzapine acts on serotonin or dopamin receptors and has antagonistic properties on histaminergic, muscarinic and α-adrenergic receptors. Olanzapine mediates the hypothermic effect through antagonism at receptors other than dopamine.
BACKGROUND
The traditional definition of hypothermia is a drop in core temperature below 35˚C. The hypothalamus, more precisely the hypothalamic pre-optic region, is assumed to work as a coordinating center with involvement of dopamine, serotonin, norepinephrin and α-adrenergic receptors [1] [2] [3] . Cerebrovascular autoregulation of our core temperature remains intact until below 25˚C; the latter helps maintain the cortical blood flow [4] . The most common causes of hypothermia are due to environmental exposure to low ambient temperatures. Other causes are septicemia, diabetic ketoacidosis, malnutrition, multisystem trauma, acute spinal cord injury, prolonged cardial arrest and hypothyroidism. Major side effects of olanzapine and other second-generation antipsychotics, like risperdone, quetiapine, aripipazole, paliperidone and ziprasidone are temperature dysregulation (mostly hyperthermia, less often hypothermia) and the neuroleptic malignant syndrome, a life threatening event. Other side effects seen by neuroleptic drugs are include sedation, weight gain, hyperglycemia, orthostatic hypotension, dizziness, constipation, urinary retention, discoloration of teeth and dental problems and occasionally seizures [3, [5] [6] [7] [8] [9] . Drug may increase triglyceride, cholesterol and transaminase levels [10] . Olanzapine (Zyprexa ® ), an atypical antipsychotic drug, is considered for the management of psychosis, and is also used off-label for treating anorexic adolescents [11] . In a recent paper were olanzapine was used for the adjunctive treatment of adolescents with anorexia nervosa; the patients treated with olanzapine have a greater illness severity, acuity and comorbidity than the control population. Despite the inherent differences between both groups, the authors were unable to draw any firm conclusions regarding the potential efficacy of olanzapine and the rate of weight gain was not statistically different between both groups [10] .
The mechanism of olanzapine-induced temperature dysregulation may include antagonism of the dopamine D2 and 5-hydroxytryptamine 2 (5HT2) receptors [9] . ) for borderline-psychotic behaviour namely, body image delusions and irritability and switched to olanzapine on day 71 because of insufficient effect on moodstabilizing. She was also on sertraline (Serlain ® ) 150 mg daily since the first day of her hospitalisation for a depressive behaveiour. During the time she took risperdone, her oral temperature was between 35.9˚C -36.3˚C.
CASE REPORT
Her physical exam was significant for an oral temperature of 34.5˚C taken in sitting position measuring with an electronic thermometer, blood pressure of 86/59 mm Hg, pulse rate of 42 bpm and an oxygen saturation of 98% in room air. Weight: 47.5 kg; Height: 162 cm and BMI was 18.1 kg/m 2 . Her heart sounds were regular and bilateral lung auscultation was clear. The extremities demonstrated mild acrocyanosis without pitting edema. Neurologic examination revealed a slurred speech and normal tendon reflexes of all extremities.
Laboratory data included the following values: a white blood cell count (WBC) of 5.9 × 10 were within the normal range. Cholesterol and triglycerides levels were also normal.
QT-and QTc intervals measured in lead II were normal during the hypothermic period and also during the further hospitalisation. A sinus bradycardia of 49 bpm without rhytm disturbances was registered on the ECG on day 141. After cessation of olanzapine the heart rate increased till 59 bpm on day 151 and till 66 bpm on day 155 when olanzapine was reintroduced (see Figure 1) .
Her temperature gradually rose spontaneously after withdrawal of olanzapine in 13 days and then continued to rise to normal following reintroduction of olanzapine at a lower dosage [2.5 mg/daily started on day 155 and 5 mg/daily started on day 164] (see Figure 1 ).
LITERATURE REVIEW
This is the twelfth reported patient with olanzapine-induced hypothermia and the youngest pediatric patient with olanzapine-induced hypothermia described in the literature (PubMed Search for olanzapine and hypothermia 13.09.2011) (see Table 1 ) [5] [6] [7] [8] [9] [12] [13] [14] [15] [16] . According to the literature, the risk of hypothermia is highest following initiation of the drug or after an increase in dosage. The most frequent diagnosis involved in these situations is schizophrenia [5] .
DISCUSSION
In the case of the anorexic girl described here, hypothermia started during the refeeding phase, when olanzapine was initiated at a rapidly increasing dosage. Hypother- mia-unrelated to drug use has already been reported in anorexic patients with a BMI < 13 kg/m 2 and latent transient primary hypothyroidism or low T3 syndrome before refeeding [17] . In contrast, onset of hypothermia developed abruptly in our patient during the refeeding phase, when the BMI had already increased to 18.1 kg/m 2 and the thyroid function tests were normal. Also risperdone used in the first weeks for borderline-psychosis can also cause hypothermia, but her oral temperature observed during that treatment was not in the hypothermic range. This is an argument in favour of olanzapine as the primary cause of her hypothermia.
OPEN ACCESS
Since the introduction of the drug in 1996 for clinical use, the database of the Adverse Drug Reactions linked in 2006 hypothermia to olanzapine use.The underlying mechanisms are still unclear. In 2000 Oerther and Ahlenus made the suggestion that olanzapine-induced hypothermia may be explained by a direct inhibitory effect on the sympathetic outflow and brown adipose tissue thermogenesis [18] .
Metabolism of olanzapine is via CYP 1A2 pathways, with no relevant genetic polymorphisms currently on record [7, 8] . It is known that in normal humans there is a balance between the down-regulation of the body temperature by dopamine and the up-regulation of the body temperature by serotonin. Hypothermia induced by olanzapine could be mediated through antagonism of mostly D2 receptors but also due to antagonism of the 5-HT 2 receptors, for which we now know that olanzapine has a high affinity [9] .
We suspect that hypotension and bradycardia in our patient were provoked by olanzapine use, namely by blockage of the α 2 -adrenergic receptors [15] . The latter might also increase the hypothermic effect by inhibiting peripheral responses to cooling of the body [9] .
SUMMARY AND CONCLUSION
Medication-induced hypothermia can go unnoticed in patients, and in extreme cases can be life-threatening. The symptoms and signs are delirium, slurred speech, ataxia, shivering, subjective coldness, fatigue, incoordination and bradycardia. These can be mistaken for symptoms seen in an acute state of undernutrition in anorexic patients. Therefore, when antipsychotic drugs are prescribed or increased in dosage, clinicians should be aware of drug-induced hypothermia. In such a context, it is necessary to monitor body temperature very carefully, registering in detail the temperature and vital signs along with the correct dosage of the drug and the time interval of increase in dose.
